Stocktoria
Kodiak Sciences Inc. KOD
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-10-04
Kodiak Sciences Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $182.4M | $126.1M | $206.3M | $267.6M | $217.3M |
| Operating income | -$234.4M | -$186.8M | -$277.3M | -$341.4M | -$267.1M |
| Interest expense | $0 | $0 | $13,000 | $18,000 | $47,000 |
| Income tax | $52,000 | $20,000 | $33,000 | $33,000 | $74,000 |
| Net income | -$230.0M | -$176.2M | -$260.5M | -$333.8M | -$267.0M |
| EPS (diluted) | $-4.32 | $-3.35 | $-4.97 | $-6.39 | $-5.16 |
| Operating cash flow | -$136.0M | -$117.3M | -$154.2M | -$206.5M | -$182.3M |
| Free cash flow | -$136.5M | -$117.7M | -$195.5M | -$243.5M | -$199.3M |
| Cash & equivalents | $209.9M | $168.1M | $285.5M | $190.4M | $731.5M |
| Total assets | $351.5M | $335.6M | $479.4M | $666.6M | $904.2M |
| Total liabilities | $194.2M | $185.3M | $213.6M | $230.5M | $240.9M |
| Shareholders' equity | $157.4M | $150.3M | $265.8M | $436.2M | $663.3M |
Source: SEC EDGAR filings · CIK 0001468748 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.